Culture Change At GSK: 'We’re Doing What We Said We’d Do'
R&D Chief Says Doubters Are Coming Round
Chief scientific offficer Hal Barron talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
You may also be interested in...
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.